Bausch + Lomb (BLCO)

Executive Summary

Bausch + Lomb is a premier global eye health company with a diversified portfolio spanning contact lenses, lens care, pharmaceuticals, and surgical devices. The company benefits from secular trends like an aging population and increasing screen time driving demand for vision correction and cataract surgeries. Recent efforts to streamline operations and focus on innovation—such as the launch of premium daily disposable lenses and next-gen intraocular lenses—have strengthened its competitive positioning. However, the company faces headwinds from generic competition in its pharmaceutical segment and a legacy debt burden from its spin-off from Bausch Health. Overall, Bausch + Lomb is well-positioned to deliver steady growth through its leading market share in contact lenses and a robust pipeline of surgical innovations.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of NOVASIL silicone hydrogel contact lens80% success
• Q4 2026Launch of next-generation enVista intraocular lens (IOL) platform70% success
• Q3 2026Q2 2026 earnings beat driven by contact lens market share gains65% success